Center for International Blood & Marrow Transplant Research (CIBMTR)

Center for International Blood & Marrow Transplant Research (CIBMTR) A Research Collaboration Between the Medical College of Wisconsin and NMDP.

CIBMTR is a research collaboration between the Medical College of Wisconsin and NMDP. CIBMTR provides a unique resource of information and expertise to the medical and scientific community. Now with data from more than 630,000 patients, more than 1,750 publications, and approximately 250 ongoing studies and clinical trials, CIBMTR is at the forefront of research to increase access to cellular therapies and to improve outcomes.

Health Care Providers: Have you ever wondered about the effects of CAR T-cells on your patients' ? Help The Leukemia & ...
07/25/2025

Health Care Providers: Have you ever wondered about the effects of CAR T-cells on your patients' ? Help The Leukemia & Lymphoma Society gather critical information by referring patients to this survey: https://form.typeform.com/to/rGw4Udaj

07/07/2025

Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more:

After a partially matched transplant, can result. Previously, partially matched donors caused more GVHD than fully mat...
07/01/2025

After a partially matched transplant, can result. Previously, partially matched donors caused more GVHD than fully matched donors in cancer patients. A new approach, using cyclophosphamide, can prevent most GVHD. And now, a clinical trial shows that partially matched transplant is safe. Read more:https://cibmtr.org/Files/Patient-Summaries/Other-Topics-Related-to-Transplant/HLA-Matching-and-Biologic-Factors/2025.06.16-AlMalki.pdf

NEW study results just published in the Journal of Clinical Oncology: Post-Transplant Cyclophosphamide-Based GVHD Prophy...
06/16/2025

NEW study results just published in the Journal of Clinical Oncology: Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Following Mismatched Unrelated Donor PBSC Transplantation. Read more:

PURPOSEAllogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. Patients from ...

In the past, people with sickle cell disease could only get if they had a fully matched donor, but with newer medicine...
06/12/2025

In the past, people with sickle cell disease could only get if they had a fully matched donor, but with newer medicines, people can get BMT from a half-matched donor, like a parent or sibling. Read more about this BMT CTN study:https://cibmtr.org/Files/Patient-Summaries/Diseases-and-Conditions/Other-Diseases/2025.02.25-Kassim.pdf

A small BMT CTN study showed that is one good option for treating sickle cell disease in teens and young adults. Learn...
06/09/2025

A small BMT CTN study showed that is one good option for treating sickle cell disease in teens and young adults. Learn more about this study:https://cibmtr.org/Files/Patient-Summaries/Diseases-and-Conditions/Other-Diseases/2024.10.29-Walters.pdf

Address

9200 W Wisconsin Avenue, Ste C5500
Wauwatosa, WI
53226

Website

Alerts

Be the first to know and let us send you an email when Center for International Blood & Marrow Transplant Research (CIBMTR) posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category

Our Story

The CIBMTR has a broad range of research activities, but our focus is narrow. Patients. They are the reason the CIBMTR exists. Patients count on us to discover and apply the best therapies that research has identified, and to never let up in our efforts to improve those therapies.